- Home
- NTLA vs ARR Comparison
NTLA vs ARR Comparison
Compare NTLA & ARR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- ARR
- Stock Information
- Founded
- NTLA 2014
- ARR 2008
- Country
- NTLA United States
- ARR United States
- Employees
- NTLA N/A
- ARR N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ARR Real Estate Investment Trusts
- Sector
- NTLA Health Care
- ARR Real Estate
- Exchange
- NTLA Nasdaq
- ARR Nasdaq
- Market Cap
- NTLA 1.2B
- ARR 1.4B
- IPO Year
- NTLA 2016
- ARR N/A
- Fundamental
- Price
- NTLA $13.60
- ARR $16.84
- Analyst Decision
- NTLA Buy
- ARR Hold
- Analyst Count
- NTLA 19
- ARR 6
- Target Price
- NTLA $35.11
- ARR $18.50
- AVG Volume (30 Days)
- NTLA 4.7M
- ARR 2.9M
- Earning Date
- NTLA 08-07-2025
- ARR 07-23-2025
- Dividend Yield
- NTLA N/A
- ARR 17.10%
- EPS Growth
- NTLA N/A
- ARR N/A
- EPS
- NTLA N/A
- ARR N/A
- Revenue
- NTLA $45,569,000.00
- ARR $20,589,000.00
- Revenue This Year
- NTLA N/A
- ARR $450.49
- Revenue Next Year
- NTLA N/A
- ARR $19.01
- P/E Ratio
- NTLA N/A
- ARR N/A
- Revenue Growth
- NTLA N/A
- ARR N/A
- 52 Week Low
- NTLA $5.90
- ARR $13.18
- 52 Week High
- NTLA $27.42
- ARR $21.08
- Technical
- Relative Strength Index (RSI)
- NTLA 65.69
- ARR 55.06
- Support Level
- NTLA $12.48
- ARR $16.35
- Resistance Level
- NTLA $14.61
- ARR $16.89
- Average True Range (ATR)
- NTLA 0.90
- ARR 0.27
- MACD
- NTLA 0.13
- ARR 0.00
- Stochastic Oscillator
- NTLA 76.33
- ARR 80.56
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.